Protalix (PLX) Says FDA Accepts Resubmission of CRL for Taliglucerase Alfa; Sets Feb. 1 as PDUFA Date
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Join SI Premium – FREE
Protalix (NYSE: PLX) announces the FDA has accepted for review its Complete Response Resubmission for taliglucerase alfa.
The FDA deemed the resubmission a class 2, or 6-month, response and established Feb. 1, 2012 as the Prescription Drug User Fee Act date.
The FDA deemed the resubmission a class 2, or 6-month, response and established Feb. 1, 2012 as the Prescription Drug User Fee Act date.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sky Quarry names Heidi Bowman as CFO
- Synaptics CFO resigns amid pending ON Semiconductor merger
- Albemarle names Max Hood as chief accounting officer
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
